Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a major pandemic. While vaccine development moves forward, optimal treatment continues to be explored. Efforts include an ever-expanding number of clinical trials along with newly proposed experimental and off-label investigational therapies; one of which is therapeutic plasma exchange (TPE). There have been a number of publications on TPE use as adjunctive therapy for coronavirus disease 2019 (COVID-19), but no prospective randomized controlled trials (RCTs) have been completed. This article critically appraises the current available evidence on TPE as a treatment modality for SARS-CoV-2 infection.
Keywords: COVID-19; SARS-CoV-2; plasma exchange.
【저자키워드】 COVID-19, SARS-CoV-2, plasma exchange, 【초록키워드】 Randomized controlled trial, Treatment, coronavirus disease, Coronavirus disease 2019, Vaccine development, coronavirus, clinical trial, pandemic, therapy, SARS-COV-2 infection, clinical trials, severe acute respiratory syndrome Coronavirus, controlled trials, plasma exchange, plasma, RCTs, Evidence, Therapeutic plasma exchange, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, off-label, while, include, TPE, 【제목키워드】 Treatment, therapy, critical appraisal, Evidence,